Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $10.02 billion. The enterprise value is $10.47 billion.
| Market Cap | 10.02B |
| Enterprise Value | 10.47B |
Important Dates
The next confirmed earnings date is Wednesday, May 1, 2024, before market open.
| Earnings Date | May 1, 2024 |
| Ex-Dividend Date | Feb 9, 2024 |
Share Statistics
Bio-Techne has 157.19 million shares outstanding. The number of shares has decreased by -1.04% in one year.
| Shares Outstanding | 157.19M |
| Shares Change (YoY) | -1.04% |
| Shares Change (QoQ) | -1.16% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 100.61% |
| Float | 155.39M |
Valuation Ratios
The trailing PE ratio is 46.61 and the forward PE ratio is 33.56. Bio-Techne's PEG ratio is 1.15.
| PE Ratio | 46.61 |
| Forward PE | 33.56 |
| PS Ratio | 8.78 |
| Forward PS | 8.29 |
| PB Ratio | 5.12 |
| P/FCF Ratio | 44.58 |
| PEG Ratio | 1.15 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.07, with an EV/FCF ratio of 46.45.
| EV / Earnings | 46.70 |
| EV / Sales | 9.14 |
| EV / EBITDA | 28.07 |
| EV / EBIT | 39.85 |
| EV / FCF | 46.45 |
Financial Position
The company has a current ratio of 4.37, with a Debt / Equity ratio of 0.28.
| Current Ratio | 4.37 |
| Quick Ratio | 2.54 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.49 |
| Debt / FCF | 2.47 |
| Interest Coverage | 23.42 |
Financial Efficiency
Return on equity (ROE) is 11.50% and return on invested capital (ROIC) is 9.50%.
| Return on Equity (ROE) | 11.50% |
| Return on Assets (ROA) | 8.40% |
| Return on Capital (ROIC) | 9.50% |
| Revenue Per Employee | $375,410 |
| Profits Per Employee | $73,495 |
| Employee Count | 3,050 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, Bio-Techne has paid $27.30 million in taxes.
| Income Tax | 27.30M |
| Effective Tax Rate | 10.86% |
Stock Price Statistics
The stock price has decreased by -20.41% in the last 52 weeks. The beta is 1.22, so Bio-Techne's price volatility has been higher than the market average.
| Beta (1Y) | 1.22 |
| 52-Week Price Change | -20.41% |
| 50-Day Moving Average | 69.96 |
| 200-Day Moving Average | 71.27 |
| Relative Strength Index (RSI) | 34.38 |
| Average Volume (30 Days) | 1,095,851 |
Short Selling Information
The latest short interest is 5.75 million, so 3.66% of the outstanding shares have been sold short.
| Short Interest | 5.75M |
| Short Previous Month | 5.32M |
| Short % of Shares Out | 3.66% |
| Short % of Float | 3.70% |
| Short Ratio (days to cover) | 4.62 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.14 billion and earned $224.16 million in profits. Earnings per share was $1.37.
| Revenue | 1.14B |
| Gross Profit | 768.64M |
| Operating Income | 268.60M |
| Pretax Income | 251.46M |
| Net Income | 224.16M |
| EBITDA | 372.91M |
| EBIT | 262.67M |
| Earnings Per Share (EPS) | $1.37 |
Balance Sheet
The company has $135.65 million in cash and $555.70 million in debt, giving a net cash position of -$420.05 million or -$2.67 per share.
| Cash & Cash Equivalents | 135.65M |
| Total Debt | 555.70M |
| Net Cash | -420.05M |
| Net Cash Per Share | -$2.67 |
| Equity / Book Value | 1.96B |
| Book Value Per Share | 12.49 |
| Working Capital | 455.41M |
Cash Flow
In the last 12 months, operating cash flow was $276.43 million and capital expenditures -$51.04 million, giving a free cash flow of $225.39 million.
| Operating Cash Flow | 276.43M |
| Capital Expenditures | -51.04M |
| Free Cash Flow | 225.39M |
| FCF Per Share | $1.43 |
Margins
Gross margin is 67.13%, with operating and profit margins of 23.46% and 19.58%.
| Gross Margin | 67.13% |
| Operating Margin | 23.46% |
| Pretax Margin | 21.96% |
| Profit Margin | 19.58% |
| EBITDA Margin | 32.57% |
| EBIT Margin | 22.94% |
| FCF Margin | 19.68% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.50%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.50% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.36% |
| Buyback Yield | 1.04% |
| Shareholder Yield | 1.55% |
| Earnings Yield | 2.23% |
| FCF Yield | 2.24% |
Analyst Forecast
The average price target for Bio-Techne is $85.44, which is 33.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $85.44 |
| Price Target Difference | 33.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 8.67% |
| EPS Growth Forecast (5Y) | 14.33% |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 9.44 and a Piotroski F-Score of 4.
| Altman Z-Score | 9.44 |
| Piotroski F-Score | 4 |